LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or “the Company”) (NASDAQ: ABEO) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abeona failed to maintain appropriate Chemical, Manufacturing, and Controls (“CMC”) procedures and compliance policies. The Company also failed to share necessary data points on transport stability of EB-101 to clinical sites. The Company should have foreseen that the FDA would reject approval for the start of a VITAL study until this failure was addressed. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Abeona, investors suffered damages.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
